Complementary Medicine for the Modification of Risk Factors for Cognitive ImpairmentView this Special Issue
Editorial | Open Access
Genevieve Z. Steiner, Sai Wang Seto, Yiu Wa Kwan, Crystal Haskell-Ramsay, David A. Camfield, "Complementary Medicine for the Modification of Risk Factors for Cognitive Impairment", Evidence-Based Complementary and Alternative Medicine, vol. 2017, Article ID 9472859, 2 pages, 2017. https://doi.org/10.1155/2017/9472859
Complementary Medicine for the Modification of Risk Factors for Cognitive Impairment
There is a natural decline in cognitive function as we age, particularly in processing speed and working memory. A range of modifiable factors can increase the risk of accelerated cognitive decline including hypertension, chronic inflammation, atherosclerosis, diabetes, atrial fibrillation, stroke, and impaired central nervous system glucose regulation. Given the lack of adequate interventions for cognitive decline and dementia, it is essential that treatments with the potential to reduce the risk of cognitive impairment are thoroughly explored.
Nutraceutical and lifestyle medicines, including vitamins, herbs, supplements, physical activity, and diet, have been shown to possess anti-inflammatory, antihyperglycaemic, and antihypertensive properties, suggesting their utility in targeting the pathophysiology associated with risk for cognitive decline. The purpose of this special issue was to explore the role of such complementary medicines in the modification of risk factors for cognitive decline.
Authors contributed with a range of papers including original research and review articles spanning in vitro, in vivo, and human studies that improve the understanding of the pathology involved in cognitive impairment in older age and the development of evidence-based complementary treatment strategies for cognitive decline. This collection of works provides a snapshot (that is by no means exhaustive) of current research and some of the emerging trends in this field. This special issue features 11 papers including 4 reviews and 7 original research articles. The complementary therapies explored include nutritional supplements (2 papers), herbal and traditional medicines (6 papers), physical activity (1 paper), and electroacupuncture (2 papers). A brief description of these 11 works is detailed below.(i)Clinical trials involving nutraceutical and herbal medicine interventions for people with mild cognitive impairment and dementia are reviewed in G. Z. Steiner et al. The manuscript titled “A Systematic Review of Intervention Studies Examining Nutritional and Herbal Therapies for Mild Cognitive Impairment and Dementia Using Neuroimaging Methods: Study Characteristics and Intervention Efficacy” focuses on papers that feature neuroimaging outcome measures.(ii)D. Chang et al. provide a detailed review of the literature on herbal medicine for vascular dementia in their paper titled “Herbal Medicine for the Treatment of Vascular Dementia: An Overview of Scientific Evidence.”(iii)Vascular disease, such as cerebrovascular disease and atherosclerosis are risk factors for cognitive impairment. X. Zhou et al. review the evidence on this link and promising Traditional Chinese Medicines in their paper titled “Vascular Contributions to Cognitive Impairment and Treatments with Traditional Chinese Medicine.”(iv)The fourth review featured in this special issue summarises the evidence on the efficacy of physical activity in reducing depression. D. C. Mathersul and S. Rosenbaum’s paper is titled “The Roles of Exercise and Yoga in Ameliorating Depression as a Risk Factor for Cognitive Decline.”(v)H. Macpherson et al. outline the findings of a clinical trial on older adults in their paper titled “The Effects of Four-Week Multivitamin Supplementation on Mood in Healthy Older Women: A Randomized Controlled Trial.”(vi)The first preclinical paper in this special issue explores the effectiveness of Huannao Yicong extract, a Traditional Chinese Medicine, in reducing tau hyperphosphorylation in Alzheimer’s disease model rats. Y. Cao et al.’s paper is titled “Traditional Chinese Medicine Huannao Yicong Decoction Extract Decreases Tau Hyperphosphorylation in the Brain of Alzheimer’s Disease Model Rats Induced by .”(vii)X. Wang et al. report their findings from an electroacupuncture treatment on Alzheimer’s disease model mice in their paper titled “Improvement of Electroacupuncture on APP/PS1 Transgenic Mice in Spatial Learning and Memory probably due to Expression of Aβ and LRP1 in Hippocampus.”(viii)The second electroacupuncture paper in this special issue explores the effects of this treatment on cerebral hypoperfusion model rats. C.-X. Zheng et al.’s paper is titled “Electroacupuncture Ameliorates Learning and Memory and Improves Synaptic Plasticity via Activation of the PKA/CREB Signaling Pathway in Cerebral Hypoperfusion.”(ix)In the paper titled “Preservation of Cognitive Function by Lepidium meyenii (Maca) Is Associated with Improvement of Mitochondrial Activity and Upregulation of Autophagy-Related Proteins in Middle-Aged Mouse Cortex” by S.-S. Guo et al., maca (a traditional Andean medicine) was found to improve cognition and behavior, and mitochondrial dysfunction in middle-aged mice.(x)In an in vitro study by L. Liu et al., the effects of Aβ-induced neurotoxicity on SH-SY5Y cells are modulated by a the Traditional Chinese Medicine, Yi-Zhi-Fang-Dai formula. The paper is titled “Yi-Zhi-Fang-Dai Formula Protects against Oligomer Induced Cell Damage via Increasing Hsp70 and Grp78 Expression in SH-SY5Y Cells.”(xi)The final paper in this special issue by M. A. Akhtar et a. titled “Medicinal Plants of the Australian Aboriginal Dharawal People Exhibiting Anti-Inflammatory Activity” explores the medicinal effects of a range of Eucalyptus plants used in traditional Australian Aboriginal medicine by the Dharawal people.
As a medical research institute, NICM receives research grants and donations from foundations, universities, government agencies, individuals, and industry. Sponsors and donors provide untied funding for work to advance the vision and mission of the Institute. The content that is the subject of this editorial was not undertaken as part of a contractual relationship with any organisation other than the funding declared in the Acknowledgements. It should also be noted that NICM conducts clinical trials relevant to this topic area, for which further details can be provided on request.
We would like to extend our gratitude to all the authors who submitted their work for consideration in our special issue and to the reviewers for their critical feedback. We hope that this collection of works provides a beacon to help direct the field in the investigation of complementary therapies for the modification of risk factors for cognitive impairment. G. Z. Steiner’s contribution to this special issue was supported by funding from an Australian National Health and Medical Research Council (NHMRC)-Australian Research Council (ARC) Dementia Research Development Fellowship (APP1102532). S. W. Seto is supported by a Cardiac Health Institute Research Fellowship.
Genevieve Z. Steiner
Sai Wang Seto
Yiu Wa Kwan
David A. Camfield
Copyright © 2017 Genevieve Z. Steiner et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.